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Abstract
Background: Late stage at diagnosis of cancer is considered a key predictor factor for a lower survival rate.
Knowing and understanding the barriers to an early diagnosis of colorectal cancer is critical in the fight to reduce
the social and economic burden caused by cancer in Puerto Rico. This study evaluates factors associated to
colorectal cancer stage at diagnosis among Puerto Rico’s Government Health Plan (GHP) patients.
Methods: We conducted a cross-sectional study based on a secondary data analysis using information from the
Puerto Rico Central Cancer Registry (PRCCR) and the Puerto Rico Health Insurance Administration (PRHIA). Logistic
regression models were used to estimate the unadjusted odds ratio (ORs) and adjusted odds ratio (AORs), and their
95 % confidence intervals (CIs). Colorectal cancer cases diagnosed between January 1, 2012 and December 31,
2012, among persons 50 to 64 years of age, participants of the GHP and with a cancer diagnosis reported to the
PRCCR were included in the study.
Results: There were 68 (35.79 %) colorectal cancer patients diagnosed at early stage while 122 (64.21 %) where
diagnosed at late stage. In the multivariate analysis having a diagnostic delay of more than 59 days (AOR 2.94, 95 %
CI: 1.32 to 6.52) and having the first visit through the emergency room (AOR 3.48, 95 % CI: 1.60 to 7.60) were strong
predictors of being diagnosed with colorectal cancer at a late stage.
Conclusions: These results are relevant to understand the factors that influence the outcomes of colorectal cancer
patients in the GHP. Therefore, it is important to continue developing studies to understand the Government
Health Plan patient’s pathways to a cancer diagnosis, in order to promote assertive decisions to improve patient
outcomes.
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Background
Stage at diagnosis is considered the most important
prognostic factor in colorectal cancer and is associated
with a lower survival rate [1]. Results from a recent
study found that colorectal cancer patients from Puerto
Rico’s Government Health Plan (GHP) are diagnosed at
more advanced stages, have worse survival, and had
greater excess risk of death compared with Non-
Government Health Plan (NGHP) patients [2]. This re-
sults justify more research to improve our knowledge
and understanding of these outcomes, moreover when
colorectal cancer is the leading cause of cancer death in
Puerto Rico [3].
Similar to the United States, the healthcare system in
Puerto Rico utilizes private healthcare providers as the
principal health services providers. Most health services
are funded principally through government funding
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(federal and local) and employer-based insurance [4].
Nearly 7 % of the island’s population is uninsured [5].
In 1994, the government of Puerto Rico started the
implementation of a managed care delivery system with
a GHP. The GHP’s main goal was the integration of
health care for the medically indigent population to the
private health sector [6, 7]. Puerto Rico’s government,
through the Puerto Rico Health Insurance Administra-
tion (PRHIA), assumed the role of contracting and over-
seeing the private insurance companies, delegating the
responsibility to provide access to health services for
medically indigent persons. The GHP beneficiaries are
limited to the Medicaid, Medicare eligible, and medically
indigent citizens with family incomes below 200 % of the
federal poverty level [8–10]. Thus, the eligibility for the
GHP beneficiaries is assigned to the office of the Medic-
aid program within the Department of Health of Puerto
Rico, based on the family income. For 2012, nearly 45 %
of Puerto Rico population had the GHP of which 5 %
were dual eligible (Medicaid and Medicare) [5].
It is important to highlight that GHP cancer patients
have a comprehensive coverage with the special coverage
provision, which seeks to facilitate the effective manage-
ment of this condition. Cancer coverage under this
provision begins upon the confirmation of a cancer diag-
nosis. Under the special coverage patients can access
specialists within the network providers and to obtain
treatments, therapies or testing to address their condi-
tion, without referral or pre-authorization. Nonetheless,
disparities in colorectal cancer outcomes have been doc-
umented among GHP patients when compared to
NGHP patients [2].
Even with the accessibility of colorectal cancer screen-
ing and the efforts to reduce the incidence and mortality
of this type of cancer, the percentage of colorectal cancer
screening within the recommended ages in Puerto Rico
is lower than the Healthy People 2020 target of 70.5 %.
According to the Behavioral Risk Factor Surveillance
System during 2012, the prevalence of adults aged 50–
59 and 60–64 who had ever had a sigmoidoscopy or col-
onoscopy was 34.1 % and 51.5 %, respectively [11].
Moreover, in Puerto Rico it has been found that having
a higher level of education and having a higher income
are associated with a greater likelihood of having had a
screening study for colorectal cancer [12, 13]. This high-
lights a health inequity that justifies more research.
The Anderson-Aday model is a theoretical framework
that is commonly used to understand and study health
care access. This model uses a systems perspective to in-
tegrate individual, environmental, and health provider
aspects associated with the decision to seek health ser-
vices [14]. All these characteristics influence people to
have more or less access to health services. Individual
characteristics, like age and sex, and comorbidities,
could represent barriers to obtain health services in a
timely manner. Similarly, health system factors for ex-
ample, lack of resources such as a low supply of gastro-
enterologists [15–18], can be a barrier to an early cancer
diagnosis.
Delay in diagnosis could be related with doctor and
system factors but can also be influenced by the patient’s
characteristics [19]. Many studies have classified delay in
cancer diagnosis and treatment into three categories: pa-
tient delay or primary delay, from first symptom to first
contact with the Primary Care Provider (PCP); doctor
delay or secondary delay, from the first contact with the
PCP to a confirmed diagnosis; and, system delay or ter-
tiary delay, the time from a confirmed diagnosis to the
time of treatment initiation [19–23]. Doctor and system
delay could give details about the health system per-
formance, for example, characteristics of the delivery
system (availability, organization, and financing). Al-
though some studies have found that reasonable delay
between diagnosis and treatment is not detrimental to
patient outcomes [1, 24], other studies state that a sig-
nificant delay due to deficiencies in the health care deliv-
ery system, could be an important factor in the patient’s
outcomes [19, 22, 25]. Meanwhile, patient delay may be
due to patients seeking health care services late and en-
tering the health care system through the emergency
room [26]. Studies have shown that patients presenting
in emergency rooms tend to have shortest delays and
more advanced disease [1, 26–28].
Delayed diagnosis may contribute to a later stage at
colorectal cancer diagnosis and can likewise have a nega-
tive outcome on quality of life, with the use of more
harmful treatments when cancer is diagnosed at an ad-
vanced stage [23, 29]. This study evaluates for the first
time individuals and health system factors associated to




The present cross-sectional study used the Puerto Rico
Central Cancer Registry (PRCCR) and the PRHIA data-
bases. The PRCCR and PRHIA have a collaboration
agreement where the PRHIA provides all claims of can-
cer patients to the PRCCR. Colorectal cancer cases were
obtained from the PRCCR, which has met the standards
for completeness and data quality [3].
In situ and invasive colorectal cancer cases diagnosed
between January 1, 2012 and December 31, 2012, among
Puerto Rico residents aged 50 to 64 years (n = 548) and
reported to the PRCCR were included. Colorectal can-
cers were defined as tumors with International Classifi-
cation of Diseases for Oncology, Third Edition (ICD-O-
3), codes C18.9-C18.0 for colon cancer and for rectal
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cancer C19.9 and C20.9. Since screening is not recom-
mended for persons under 50 years [30], these persons
were excluded. On the other hand, individuals over
64 years were not included because most of them have
Medicare, therefore, a different insurance coverage. Only
cases with diagnostic confirmation of colorectal cancer
were included in the analysis. Patients with unknown
method of confirmation, unknown stage at diagnosis
and reported to the PRCCR by the death certificate only
or autopsy were excluded (n = 35). In addition, patients
who have had another cancer diagnosis before or within
2 years after the colorectal cancer diagnosis were also
excluded (n = 12). After obtaining the eligible incident
cases of colorectal cancer diagnosed in 2012, a probabil-
istic match using LinkPlus V.2.0 was performed to deter-
mine GHP patients and to assign all claims by patient.
Once the GHP patients were identified in the PRCCR, a
review was performed to classify them in order to ensure
the validity of the data.
For purposes of this study, stage at diagnosis was cate-
gorized into a dichotomous category: early stage (in situ
and localized) and late stage (regional and distant), using
the Derived SEER Summary Stage 2000. Other patient
characteristics variables considered were age at diagnosis
(grouped into three categories: 50–54, 55–59, and 60–64
years), and sex. Marital status at the time of diagnosis
was classified as married (including common law or do-
mestic partner) and unmarried (never married, sepa-
rated, divorced, and widowed). Primary site was
categorized as colon and rectum. Comorbidity was
assessed using the Charlson Comorbidity Index, which
consideres 17 comorbidities found to be related with 1-
year mortality, and assigned a weighted score to each co-
morbid condition that represents a measure of the bur-
den of comorbid disease [31]. We used the algorithm
developed by Quan et al. [32] and a Stata module to cal-
culate the index [33]. Charlson index score was classified
as 0, 1 and ≥2.
In order to evaluate health delivery system characteris-
tics, we examined if the type of primary care had an ef-
fect in the stage at diagnosis among colorectal cancer
GHP patients. Patients were classified according to the
type of primary medical group (PMG) to which they
belonged. Federally Qualified Health Centers (FQHC)
were compared to the other PMGs. Also, GHP regions
were classified according to gastroenterologist supply.
The regions are composed by West, Southwest, North-
ern, Southeast, Metro-North, East, San Juan and, North-
east Region. Gastroenterologist’s rate per GHP region
was obtained from the PRHIA and was classified as hav-
ing high (≥8.00), medium (4.00–7.99), and low (0–3.99)
gastroenterologist’s rate.
This study also evaluated diagnosis delay, in order to
determine if patients with longer delays had more
advanced stage at diagnosis. Diagnosis delay was defined
as the time in days between the patient’s first contact
with the health care system to a cancer diagnosis. Previ-
ous studies have also defined diagnosis delay as time
from the patient’s first contact with the health care sys-
tem to cancer diagnosis [1, 34]. In addition, it has been
reported that diagnosis delay outcomes such as stage at
diagnosis and death are not linear, thus, patients with
shortest delays can have a higher risk of death [1]. Thus,
we categorized the diagnosis delay variable into a cat-
egorical variable: <14 days, 14–59 days (reference), and
≥60 days.
To analyze possible patient delay we created a dichot-
omous variable indicating if the patient’s first contact
with the health care system for a colorectal cancer diag-
nosis was through the emergency room. First contact
with the health care system was determined as the first
visit of the patient with colorectal cancer related symp-
toms (abdominal pain, constipation, anemia, weight loss,
rectal bleeding, among others) prior to a colorectal can-
cer diagnosis. In the absence of this type of claims, we
chose the date of the visit prior to the first gastrointes-
tinal investigation, before the colorectal cancer diagnosis.
The colorectal cancer symptoms are based on the symp-
toms used in another study [35]. The first gastrointes-
tinal investigation included abdominal radiological
imaging, lower gastrointestinal endoscopy and, fecal oc-
cult blood test (FOBT).
Statistical methods
Descriptive statistics and frequency analyses were used
to describe the variables of interest. To evaluate the dif-
ference in stage at diagnosis and the independent vari-
ables of interest, a Chi-square test of Fisher exact tests
were used. Logistic regression models were used to esti-
mate the unadjusted odds ratios (ORs), adjusted odds ra-
tios (AORs), and their 95 % confidence intervals (CIs).
The likelihood ratio test was used to assess the signifi-
cance of interaction terms. Likewise, we assessed multi-
collinearity among independent variables before
performing the multivariate logistic regression analysis.
Statistical analyses were performed using Stata/SE ver-
sion 13.1 statistical software (Stata Corp., LP., College
Station, TX).
The Institutional Review Board of the University of
Puerto Rico, Medical Sciences Campus, reviewed and
approved this study.
Results
In 2012, from a total of 548 cases of colorectal cancer
that were diagnosed in Puerto Rico between the ages of
50–64 years, 35.06 % (190 cases) were GHP patients eli-
gible for analyses. The median age was 59 years. There
were 68 (35.79 %) cases diagnosed at early stage while
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122 (64.21 %) where diagnosed at late stage. Table 1 pre-
sents the comparison of the population characteristics
by stage at diagnosis. According to the bivariate analysis,
there was no association between the stage at diagnosis
and the variables of sex, age group, marital status and
type of primary center (p-value > 0.05). While 46.84 % of
all patients had a Charlson comorbidity index of two or
more comorbidities, there was not significant difference
in terms of comorbidities and stage at diagnosis.
In regards to delay in cancer diagnosis, there were sig-
nificant differences by stage at diagnosis (p < 0.05). Out
of all patients diagnosed in early stage, 45.59 % had a
diagnostic delay between 14 and 59 days, while 41.80 %
of patients diagnosed at advanced stage had a diagnostic
delay of more than 60 days. Similarly, when we exam-
ined the variable that indicates if the patient’s first con-
tact with the health care system for a cancer diagnosis
was or not through the emergency room, we found a
statistically significant difference (p < 0.05) between this
variable and stage at diagnosis. Among colorectal cancer
patients diagnosed at late stage, 44.26 % presented at the
emergency room as a first contact for a cancer diagnosis,
Table 1 Characteristics of GHP patients, by stage at diagnosis, Puerto Rico 2012
Variable Early stage N (%) Late stage N (%) Total N (%) χ2 p-value
All 68 (35.79) 122 (64.21) 190 (100.00)
Median age (years)a 59 59 59 0.7499a
Age group (years)
50–54 11 (16.18) 27 (22.13) 38 (20.00) 0.475
55–59 28 (41.18) 41 (33.61 69 (36.32)
60–64 29 (42.65) 54 (44.26) 83 (43.68)
Sex
Male 36 (52.94) 69 (56.56) 105 (55.26) 0.631
Female 32 (47.06) 53 (43.44) 85 (44.74)
Marital status
Unmarried 29 (42.65) 65 (53.28) 94 (49.47) 0.160
Married 39 (57.35) 57 (46.72) 96 (50.53)
Charlson comorbidity index
0 15 (22.06) 35 (28.69) 50 (26.32) 0.092
1 14 (20.59) 37 (30.33) 51 (26.84)
≥2 39 (57.35) 50 (40.98) 89 (46.84)
Primary site
Colon 43 (63.24) 91 (74.59) 134 (70.53) 0.100
Rectum 25 (36.76) 31 (25.41) 56 (29.47)
Type of primary center
Non FQHC 60 (88.24) 109 (89.34) 169 (88.95) 0.815
FQHC 8 (11.76) 13 (10.66) 21 (11.05)
Delay in diagnosis (days)
<14 18 (26.47) 33 (27.05) 51 (26.84) 0.091
14–59 31 (45.59) 38 (31.15) 69 (36.32)
≥60 19 (27.94) 51 (41.80) 70 (36.84)
First visit at ER
No 51 (75.00) 68 (55.74) 119 (62.63) 0.009
Yes 17 (25.00) 54 (44.26) 71 (37.37)
Region gastroenterologist rate (per 10,000)
High rate (≥8.00) 12 (17.65) 18 (14.40) 30 (15.54) 0.671
Medium rate (4.00–7.99) 20 (29.41) 44 (35.20) 64 (33.16)
Low rate (0–3.99) 36 (52.94) 63 (50.40) 99 (51.30)
aWilcoxon statistics p-value
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while, only 25.00 % of patients diagnosed at early stage
presented at the emergency room as a first contact for a
cancer diagnosis (Table 1).
Table 2 presents the univariate and multivariate
models predicting the stage at diagnosis by predictor
variables. Of all factors studied, only delay in diagnosis
and first visit through the emergency room were statisti-
cally significant in the univariate logistic regressions. On
univariate analysis, patients who had a diagnostic delay
of more than 59 days were 2.19 times more likely to be
diagnosed in late stage compared to those who had a
diagnostic delay between 14 and 59 days (OR 2.19, 95 %
CI: 1.08 to 4.45). Whereas patients for whom the first
visit was through the emergency room had 2.38 times
the possibility of having a late stage at diagnosis than pa-
tients whose first visit was through a medical office visit
(OR 2.38, 95 % CI: 1.24 to 4.59). Nevertheless, in the
analysis that controlled for all factors considered, having
a diagnostic delay of more than 59 days (OR 2.19 vs
AOR 2.94) and having the first visit through emergency
room (OR 2.38 vs AOR 3.48) were strong and consistent
predictors of being diagnosed at late stage. Results from
the multivariate logistic regression model showed that
patients who had a diagnostic delay of more than 59 days
had almost three-fold greater possibility of having a late
stage at diagnosis than patients who had a diagnostic
delay between 8 and 59 days, after adjusting for others
factors (AOR 2.94, 95 % CI: 1.32 to 6.52). Likewise,
Table 2 Univariate and multivariate analyses for factors associated with late stage at diagnosis, Puerto Rico 2012
Variable Univariate OR (95 % CI) p-value Multivariate AOR (95 % CI) p-value
Age group (years)
50–54 1.00 [Reference] 1.00 [Reference]
55–59 0.60 (0.25, 1.40) 0.234 0.59 (0.23, 1.53) 0.281
60–64 0.76 (0.33, 1.75) 0.516 0.86 (0.34, 2.2) 0.75
Sex
Male 1.00 [Reference] 1.00 [Reference]
Female 0.86 (0.48, 1.57) 0.631 0.92 (0.47, 1.79) 0.802
Marital status
Unmarried 1.00 [Reference] 1.00 [Reference]
Married 0.65 (0.36, 1.19) 0.161 0.77 (0.4, 1.49) 0.439
Charlson comorbidity index
0 1.00 [Reference] 1.00 [Reference]
1 1.13 (0.48, 2.68) 0.777 1.04 (0.39, 2.82) 0.933
≥2 0.55 (0.26, 1.15) 0.111 0.45 (0.19, 1.03) 0.06
Primary site
Colon 1.00 [Reference] 1.00 [Reference]
Rectum 0.59 (0.31, 1.11) 0.101 0.48 (0.23, 0.98) 0.045
Type of primary center
Non FQHC 1.00 [Reference] 1.00 [Reference]
FQHC 0.89 (0.35, 2.28) 0.815 0.7 (0.24, 2.01) 0.504
Delay in diagnosis (days)
<14 1.50 (0.71, 3.15) 0.290 0.93 (0.39, 2.2) 0.862
14–59 1.00 [Reference] 1.00 [Reference]
≥60 2.19 (1.08, 4.45) 0.030 2.94 (1.32, 6.52) 0.008
First visit at ER
No 1.00 [Reference] 1.00 [Reference]
Yes 2.38 (1.24, 4.59) 0.008 3.48 (1.6, 7.6) 0.002
Region gastroenterologist rate (per 10,000)
High rate (≥8.00) 1.00 [Reference] 1.00 [Reference]
Medium rate (4.00–7.99) 1.47 (0.60, 3.61) 0.41 2.05 (0.73, 5.78) 0.174
Low rate (0–3.99) 1.17 (0.50, 2.70) 0.72 1.7 (0.64, 4.49) 0.284
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patients for whom the first visit was through the emer-
gency room had 3.48 times the possibility of having a
late stage at diagnosis than patients whose first visit were
through a medical office visit (AOR 3.48, 95 % CI: 1.60
to 7.60). When we evaluated primary site the univariate
OR was not statistically significant (p > 0.05) but, in the
multivariate analysis we observed that rectum cancer pa-
tients have a lower possibility of being diagnosed at late
stage (AOR 0.48, 95 % CI 0.23 to 0.98) in comparison
with colon cancer patients. Socio-demographic factors
including age, sex, and marital status had no significant
effect on being diagnosed at late stage in the study
population. While, colorectal cancer patients with higher
levels of comorbidity (2 or more) were more likely to
have an early stage diagnosis (AOR 0.45, 95 % CI 0.19 to
1.03), but this association was not statistically significant
(p = 0.06). In terms of variables related to the delivery of
health care, like type of primary center or gastroenter-
ologist rate, these did not reach statistical significance
(p > 0.05).
To assess whether there are variations between the
groups in the health care delivery system variables, we
used a multilevel generalized linear mixed-effects model
to determine the potential effects of the health system
variables (gastroenterologist rate and type of primary
center) on stage at diagnosis. The multilevel models
proved to have no significant effect on stage at diagnosis
of colorectal cancer patients (p > 0.05) (data not shown).
Discussion
Early diagnosis of cancer is a key factor to obtain the
best possible health outcome. A previous study found
that the majority of the GHP colorectal cancer patients
are diagnosed at late stage [2]. With the purpose of un-
derstanding this finding, the main objective of this study
was to assess the individuals and health system factors
associated to colorectal cancer stage at diagnosis among
GHP patients in Puerto Rico. This study shows that
more than one third (36.84 %) of the study population
had a delay in diagnosis of ≥ 60 days. The principal find-
ings of this study was that after controlling for factors
that could explain stage at diagnosis, the stronger pre-
dictor factors associated with stage at diagnosis was hav-
ing 60 days or more in delay at diagnosis, and having
the first contact with the health care system for a cancer
diagnosis through the emergency room. These findings
are consistent with other studies [27, 36–41]. These re-
sults are relevant in order to understand the factors that
influence the health outcomes of this population. It has
been found that there are persistent barriers related to
the patients, physicians, and the health care system, that
impede that patients gain access to medical care in a
timely manner [15, 17]. A factor that may influence
delay in diagnosis is the communication between the
doctor and the patient. It has been found that the quality
of a physician’s communication about cancer care could
vary by patient’s social class, where the physician’s com-
munication is worst in lower social class [15, 17, 23].
More research is needed to determine whether the com-
munication between the doctor and the patient is indeed
a factor in the delay in diagnosis for GHP colorectal can-
cer patients in Puerto Rico.
Another important result of this study was the high pro-
portion of patients having the first contact with the health
care system for a cancer diagnosis through the emergency
room, since this increased the likelihood of being diag-
nosed at late stage. This result is relevant since these pa-
tients were in a group of age (50–64 years) where the use
of screening tests is recommended. Furthermore, through
the GHP these patients are assigned a PCP that has the re-
sponsibility to coordinate their care. This finding may be
due to several factors. First, an important factor to con-
sider is patient delay, from the first symptom to the first
contact with the health care system or PCP. Patient delay
is usually defined as the interval of time a patient becomes
aware of symptoms before seeking medical care [23]. This
finding suggests that visits to PCPs did not occurr in a
timely manner. Studies have found that the socioeconomic
aspects related to a colorectal cancer patient are associ-
ated to emergency presentation [40, 42–45]. Socioeco-
nomic factors such as a low socioeconomic status, being
unmarried and old age are associated to emergency pres-
entation [40]. Studies have also found that lower socioeco-
nomic status was related with a reduced likelihood of
colorectal cancer screening [46–49]. This fact is relevant
since the population of this study have a lower socioeco-
nomic level. In a recent study we evaluated the factors as-
sociated with the use of emergency room as an entry
point to the health care system among GHP colorectal
cancer patients and we found that, compared to women,
males had two times the possibility of an ER presentation
[50]. This suggests that interventions focused on males
could reduce the ER presentation.
Another possible explanation for this could be that pa-
tients did not receive physician referrals. Physician refer-
rals are one of the most important factors for the patient
to receive an early cancer detection [17]. A possible rea-
son for a physician delay (mainly PCP’s) in providing a
referral, for either a diagnostic test or a specialist assess-
ment, may be related to the physician’s knowledge of the
required colorectal cancer screening and their capacity
to detect colorectal cancer early symptoms. Others bar-
riers that could have an influence on ER presentation
could include reimbursement and financial forces among
PCP. In a managed care organization, the PCPs act as
gatekeepers, who often have financial incentives to
minimize specialty referrals [15, 17, 51], which may re-
sult in a barrier to a specialty cancer care.
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Another factor that could explain, in part, that patients
presenting at the emergency room had more advanced
stage, is the fact that these patients have tumors that are
more aggressive. This result warrants further research to
understand the role and implications of the emergency
room presentations in the outcomes of colorectal
cancer.
We found no evidence to suggest that demographic
characteristics like age, sex, and marital status were asso-
ciated with stage at diagnosis. This may be due to that
fact that behavior, lifestyle, or cultural context does not
differ substantially among the low socioeconomic popu-
lation of this study. It is worth mentioning that this
population, being homogeneous in terms of health insur-
ance coverage and similar in socioeconomic status, elim-
inates most of the potential confounding effects of these
variables. Whereas, although not statistically significant,
patients with a comorbidity index of two or more had a
greater possibility to have early stage at diagnosis than
patients without comorbidities. Similar findings have
been found in other studies [52–54]. It is possible that
these patients tend to have more medical follow-up
visits, which could yield an early diagnosis [55, 56].
We also found no evidence to suggest that the health
care system delivery factors evaluated (primary center
and region gastroenterologist rate) were associated with
stage at diagnosis. Thus, this study underscores the im-
portance to further evaluate others variables related
mainly to healthcare delivery, including organizational
and structural related variables, which could have an in-
fluence on the delay of colorectal cancer diagnosis. We
used the Anderson and Aday model as a framework to
explain the access and utilization among GHP patients.
According to the Aday and Anderson model, the charac-
teristics of the health care delivery system consist of re-
sources and organization elements [57]. Resource refers
to the human resources and the capital allocated to
health care whereas, organization means the way in
which the system uses its resources. Future evaluation of
other system’s characteristics that determines what hap-
pens following the entry into the system could be im-
portant in order to clarify and expand on the current
findings.
Several limitations of this study must be acknowl-
edged. First, since there are different operational defini-
tions of delay in diagnosis, it is difficult to compare our
results with other studies. Another limitation is the use
of claims to estimate a patient’s first contact with the
health care system, since claims data are designed for
the purpose of reimbursement, not for research. How-
ever, the linkage with the PRCCR and PRHIA database,
allowed us to validated claims data quality. In addition,
we were able to complement demographic, clinical and
tumor related variables with information obtained from
the claims data, which permitted us to examine the fac-
tors associated with late stage at diagnosis in patients
with colorectal cancer in the GHP. However, we were
unable to include variables related to tumor aggressive-
ness, such as tumor grade due to a high proportion of
patients with unknown tumor grade. Similarly, variables
related to family history were not available. This type of
variable is important since screening recommendation
could vary according to the family history of cancer and
should be included in subsequent studies. Finally, an-
other limitation of the study was that we were able to
analyze data from just 1 year (2012), restricting the sam-
ple size. Despite that, this was a population-based sam-
ple that included all eligible patients and diagnosis
within the study period.
Various research opportunities arise from this study in
order to provide further clarification and expand on
current knowledge. Further studies are needed to evalu-
ate the access to quality healthcare among GHP patients.
Studying the GHP patient’s pathways to a cancer diagno-
sis could prove to be beneficial in gaining additional
knowledge in quality healthcare access. Also, including
NGHP patients could be important to evaluate the dif-
ferences between GHP patients and NGHP patients.
It is important to point out that GHP provides pre-
ventive services, like colorectal screening tests without
cost-sharing, but the use of colorectal cancer screening
in Puerto Rico is still very low. Therefore making the
screening tests accessible must be accompanied by an
increased awareness. The GHP should focus attention
on not only improving access to colorectal cancer
screening but also changing attitudes about the import-
ance of screening. We can conclude that providing
coverage of cancer screening alone has not been suffi-
cient to remove barriers to health care among GHP
population.
Conclusions
This study provides valuable information for policy
makers to improve health outcomes among the GHP
population. In 2004, Law number 230 was approved
to create the University of Puerto Rico Comprehen-
sive Cancer Center (UPRCCC), the entity in charge to
execute the public policy related to cancer prevention,
education, and research [58]. The UPRCCC developed
a Comprehensive Cancer Control Plan to establish
how to better address the cancer burden, driven by
evidence-based approaches for action [59]. Developing
and disseminating this type of studies help to estab-
lish specific strategies to promote screening among
GHP patients, and to reduce the delay at diagnosis,
among others. In addition, strengthening collabora-
tions with entities like the Colorectal Cancer Coali-
tion of Puerto Rico, could be an effective strategy to
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promote continuous programs that support colorectal
cancer screening awareness.
The GHP is focused on integrated care, thus, it is ex-
pected that primary care, through a PCP, plays a central
role in the health care delivery system. Consequently,
primary care is a critical component of the GHP in order
to provide quality access to health care services. Never-
theless, it has been observed that GHP patients are diag-
nosed at more advanced stages, and that the delay in
diagnosis and the presentation at emergencies rooms
have an influence in this outcome. It is important to
raise awareness among primary physicians to facilitate
patient’s access to recommended screening tests and to
help GHP beneficiaries to understand the importance of
performing the screening tests on time.
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